MetaCap

Cellectis S.A. (CLLS) vs NovaBridge Biosciences (NBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cellectis S.A. (CLLS) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 80.4% versus a loss of 80.4%. Over five years, CLLS leads with a -89.4% price change compared with -98.7% for NBP. NovaBridge Biosciences is the larger company by market cap ($96.3 million vs $92.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLLS-80.36%NBP-80.38%
+19%-34%-86%
Nov 21, 20251 yearNov 20, 2026
CLLS-89.66%NBP-98.79%
+7%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLLS versus NBP key metrics
MetricCLLSNBP
Share price$0.9209$0.83
Market cap$92.76M$96.28M
1-day change-7.89%-5.66%
YTD return-80.97%-79.15%
1-year return-80.36%-80.38%
5-year return-89.40%-98.69%
EPS (TTM)$-1.26$-0.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.95M—
Revenue growth (YoY)+75.76%—
Net income (latest FY)$-67.59M$-46.27M
Gross margin100.00%—
Operating margin-45.34%—
Net margin-92.66%—
52-week high$5.45$5.19
52-week low$0.881$0.751
Distance from 52-week high-83.10%-84.01%
Analyst consensusbuystrong_buy
Avg. price target upside+497.24%+944.58%
Average volume115.00K515.66K
Shares outstanding72.73M116.00M
Employees22430
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cellectis S.A.

CLLS stock →

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).

Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees

About NovaBridge Biosciences

NBP stock →

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.

Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees

CLLS vs NBP FAQ

Which is bigger, Cellectis S.A. or NovaBridge Biosciences?

NovaBridge Biosciences (NBP) is larger, with a market capitalization of $96.28M compared with $92.76M for Cellectis S.A. (CLLS).

Which stock has performed better over the past year, CLLS or NBP?

CLLS returned -80.36% over the past 12 months, compared with -80.38% for NBP (price return, excluding dividends). Past performance does not predict future results.

Are Cellectis S.A. and NovaBridge Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons